Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Prepaid Assets for 6 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 18.03% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Dec 2025, up 18.03%, and an annual FY2025 reading of $3.5 million, up 18.03% over the prior year.
  • Prepaid Assets was $3.5 million for Q4 2025 at SAB Biotherapeutics, up from $1.8 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $3.6 million in Q2 2025 and bottomed at $102742.0 in Q3 2021.
  • Average Prepaid Assets over 5 years is $1.9 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Prepaid Assets surged 1038.56% in 2022, then plummeted 59.57% in 2023.
  • Year by year, Prepaid Assets stood at $2.6 million in 2021, then tumbled by 43.33% to $1.5 million in 2022, then skyrocketed by 56.68% to $2.3 million in 2023, then grew by 27.16% to $3.0 million in 2024, then grew by 18.03% to $3.5 million in 2025.
  • Business Quant data shows Prepaid Assets for SABS at $3.5 million in Q4 2025, $1.8 million in Q3 2025, and $3.6 million in Q2 2025.